Go Mediaction

Main Menu

  • Home
  • Medical field
  • Prescription drugs
  • Drug discovery
  • Medical diagnosis

Go Mediaction

Header Banner

Go Mediaction

  • Home
  • Medical field
  • Prescription drugs
  • Drug discovery
  • Medical diagnosis
Drug discovery
Home›Drug discovery›AnaBios presents high-quality primary human liver cells for preclinical drug discovery

AnaBios presents high-quality primary human liver cells for preclinical drug discovery

By Deborah A. Gray
March 24, 2022
0
0

Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.


SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) — Today, AnaBios announced that it will begin supplying high-quality primary human liver cells to pharmaceutical, biotech and academic laboratories to further enhance research success preclinical on drug discovery.

Human livers are obtained from ethically consenting donors for research purposes. Hepatocytes are then isolated from the liver by AnaBios’ team of experts using a proprietary method. High-quality hepatocytes are an essential reagent for successful clinical development, with hepatocyte-based assays helping to define the absorption, distribution, metabolism, and excretion (ADME) profiles of new drugs. Moreover, primary human hepatocytes are essential to understand the potential hepatotoxicity of new therapies. With this new area of ​​focus, AnaBios continues its mission to develop important new ex-vivo human models to improve drug discovery.

“AnaBios is delighted to provide high quality hepatocytes to the research community,” said Dr. Andre Ghetti, Chief Executive Officer of AnaBios. “We understand the importance of hepatocytes in drug discovery and are committed to leveraging our expertise in human tissue recovery and cell isolation to produce a variety of different donor lots to meet the needs of our clients.

AnaBios is pleased to announce Orlando Mendoza as Director of Business Development for the new liver cell business. Mendoza will help guide the company’s strategic growth plan in this important area of ​​preclinical drug discovery. He joins AnaBios from Promethera Biosciences DBA Novabiosis, where he helped establish and grow their business for subsequent acquisition.

“AnaBios hepatocytes are unique in terms of batch diversity and volume, in addition to their quality,” Mendoza said. “I am extremely excited to help AnaBios become a leading provider of hepatocytes by working with our talented team of scientists to deliver a personalized end-user experience. »

About AnaBios

Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced human-focused translational technologies. AnaBios primarily focuses on areas of high and unmet medical need, including heart disease, lung disease, CNS disorders, pain, and itching. As a preclinical CRO, AnaBios has the largest network of hospitals and transplant centers to obtain human tissue samples from ethically consented donors for ex-vivo To analyse. For more information about AnaBios, visit http://www.anabios.com.

CONTACT:Chris Mathes, Ph.D.Chief Commercial OfficerEmail: [email protected]

This content was published via the newswire.com press release distribution service.

main logo

Source: Ana Bios

Categories

  • Drug discovery
  • Medical diagnosis
  • Medical field
  • Prescription drugs

Recent Posts

  • Fujitsu and RIKEN launch joint research on drug discovery technology using Fugaku
  • Medical diagnostics and technology reshaping medical communication
  • Drug discovery pioneer Verseon achieves breakthrough once predicted by Steve Jobs
  • World’s first 3D insights into malaria parasites bolster drug discovery pipeline
  • Legal weed lowers prescription drug use, study finds

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • November 2020
  • September 2020
  • May 2020
  • March 2020
  • September 2019
  • May 2019
  • August 2018
  • December 2013
  • Privacy Policy
  • Terms and Conditions